Drug Profile
Research programme: anaplastic lymphoma kinase inhibitors - Novartis
Alternative Names: NPM-ALK inhibitor; NVP-TAE684; TAE 684Latest Information Update: 20 Jul 2010
Price :
$50
*
At a glance
- Originator Novartis
- Developer Novartis; Scripps Institutions of Medicine and Science
- Class Small molecules
- Mechanism of Action Anaplastic lymphoma kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Lymphoma
Most Recent Events
- 19 Jul 2007 Preclinical trials in Lymphoma in USA (unspecified route)